ESTRO 2024 - Abstract Book

S1886

Clinical - Mixed sites, palliation

ESTRO 2024

No systemic therapy

6 (18.8)

Total number of OM, n (%) §

1 2 3 4 5

22 (68.8)

3 (9.4) 2 (6.2) 3 (9.4) 2 (6.2)

Dose and fractionation, n (%) ^

30-35 Gy/5 fractions 40-50 Gy/5 fractions

9 (25.7) 16 (45.7) 10 (28.6) 70 (48-72)

Other

BED10, Gy, median (IQR) ^ GTV, cc, median (IQR) ^ PTV, cc, median (IQR) ^

11.8 (8.9-23.9)

41.7 (29.3-61.4)

AGMs: adrenal gland metastases; IQR: interquartile range; OM: treated oligo-metastases; Gy: gray; BED: biological effective dose; GTV: gross tumor volume; PTV: planning target volume; cc: cubic centimeters.

* per patient

^ per lesion

§ per radiotherapy course

° 3 patients with bilateral AGMs irradiation, and 1 patient treated after contralateral adrenalectomy

Fig. 1. Target volumes, prescribed dose distribution, post-treatment response in a patient treated with SBRT for AGM.

Adrenal gland metastasis with close proximity to duodenum (GTV in cyan, PTV in red, duodenum in blue)

Inhomogeneous distribution of prescribed dose (40 Gy in 5 fx to GTV; 30 Gy in 5 fx to PTV) allowed adherence to duodenum dose constraints without compromising